5-amino-1mq and cd38 inhibitor synergy nad+ Heavy-chain antibody targeting of hydrolase ectoenzyme to prevent fibrosis in multiple organs The Pharmacology of CD38/NADase: An
The Pharmacology of CD38 NADase: An emerging target for cancer and aging diseases PMC SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS driven AML: Cell Metabolism Rapid Discovery of CD38 Inhibitor via DNA Encoded Natural Product Library Screening
Pay in 4 interest-free payments of $6.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



